KIU Journal of Health Sciences
December 22, 2024
Idehen I C, O Yibala, Yakubu B S et al.
In all vertebrates and the majority of invertebrates, the brain is the organ that acts as the hub of the nervous system. 3,4-methylenedioxymethamphetamine (MDMA), a derivative of amphetamine that affects the central nervous system (CNS), is marketed under the brand name Molly and is abused for its intoxicating recreational effects. Using adult Wistar rats, this study sought to ascertain the...
Frontiers in Human Neuroscience
December 11, 2024
Scott Shannon, Jamarie Geller
3 citations
We are experiencing a mental health crisis of unprecedented proportions. Over the last two decades this crisis grew from a perfect storm of rising insurance deductibles, escalating social stressors, the COVID-19 pandemic, and a critical workforce deficiency. Perhaps no mental health arena has a greater shortfall of effective treatment options than Post-traumatic Stress Disorder (PTSD) as the...
The Science of the total environment
December 10, 2024
Ondina Ribeiro, Luís Félix, Cláudia Ribeiro et al.
1 citation
The increased detection of the recreational drug 3,4-methylenedioxymethamphetamine (MDMA) in aquatic ecosystems, has raised concern worldwide about its possible negative impacts on wildlife. MDMA is produced as racemate but its enantioselective effects on non-target organisms are poorly understood. Therefore, this study aimed to provide a comprehensive study of the toxicity of MDMA and its...
International Journal of Psychology
December 6, 2024
Monica Schweickle, Ted Cassidy
Purpose: The goal of this case report is to illustrate the implementation of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder (PTSD) and learning points for health professionals in the translation of psychedelic assisted therapy research into clinical practice. We present our key learnings and 6-month follow up data from one of the first patients to...
Neuropsychopharmacology
December 1, 2024
Isabelle Straumann, Isidora Avedisian, Aaron Klaiber et al.
20 citations
Racemic 3,4-methylenedioxymethamphetamine (MDMA) acutely increases mood, feelings of empathy, trust, and closeness to others and is investigated to assist psychotherapy. Preclinical research indicates that S-MDMA releases monoamines and oxytocin more potently than R-MDMA, whereas R-MDMA more potently stimulates serotonin 5-hydroxytryptamine-2A receptors. S-MDMA may have more stimulant...
Neuropsychopharmacology Reports
December 1, 2024
Ghada Shahrour, Kainat Sohail, Safa Elrais et al.
21 citations
Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating symptoms. Despite available treatments, many individuals experience inadequate response or significant side effects. Previous reviews suggest promising outcomes with MDMA-assisted psychotherapy (MDMA-AT), but limitations prompt the need for a...
Journal of Affective Disorders
November 15, 2024
Abigail E. Calder, Gregor Hasler
20 citations
Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effects. Measuring side effects is challenging because they are not always easily differentiated from treatment effects or disease symptoms and show high heterogeneity, variable duration and impact, and sensitivity to context. A systematic questionnaire...
Scientific Reports
November 14, 2024
Erin Wang, David S. Mathai, Natalie Gukasyan et al.
18 citations
Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression...
JAMA Network Open
November 4, 2024
Cihan Atila, Isabelle Straumann, Patrick Vizeli et al.
15 citations
3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. Acute hyponatremia is a potentially serious complication after even a single dose of MDMA. The assumed etiology has been a vasopressin release inducing the syndrome of inappropriate antidiuresis combined with increased thirst, causing polydipsia and...
JAMA Psychiatry
November 1, 2024
Ioana Alina Cristea, Pim Cuijpers, Joar Øveraas Halvorsen
This Viewpoint discusses the critical yet overlooked role of the psychotherapy component in assessing the validity of the trials of midomafetamine/3,4-methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder.